Larazotide vs Plecanatide
Head-to-head comparison of Larazotide (Larazotide acetate (AT-1001)) and Plecanatide (Plecanatide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Larazotide | Plecanatide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Larazotide acetate (AT-1001) | Plecanatide |
| Molecular Weight | N/A | Approx. 1620 Da |
| Half-Life | short; designed for local gut action | Local intestinal action; systemic half-life not clinically meaningful |
| Amino Acids | 8 | 16 |
| Typical Dose | 0.5-4 mg TID (clinical studies) | 3 mg once daily |
| Route | Oral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 350 |
| Research Status | Clinical | Clinical |
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Research Overview
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.